Vir Biotechnology Inc (VIR) News & EventsVIRVir Biotechnology Inc

Vir Biotechnology Collaborates with Gilead to Develop Novel T-Cell Engagers

Vir Biotechnology (VIR) announced a collaboration and license agreement with Gilead (GILD) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager, TCE, development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its proprietary dAIsY platform for rapid, multiparameter optimization of high-quality TCEs and the universal PRO-XTEN masking technology.

Vir Biotechnology Receives FDA Fast Track Designation

Vir Biotechnology (VIR) announced that the U.S. Food and Drug Administration, FDA, granted Fast Track designation, FTD, to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, TCE, for the treatment of late-line metastatic castration-resistant prostate cancer, mCRPC. VIR-5500 is being co-developed by Astellas Pharma (ALPMY) and Vir Biotechnology through a global strategic collaboration. "Receiving Fast Track designation reflects the potential of VIR-5500 to address an area of serious unmet need in late-line mCRPC and the strong momentum we have achieved with Astellas as we prepare to enter pivotal Phase 3 development in 2027," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. "We look forward to working with the FDA to rapidly advance the development of VIR-5500 for people living with mCRPC."

Vir Biotechnology Appoints Dr. David Liu as Chief Medical Officer

Vir Biotechnology (VIR) announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. Liu joins Vir Biotechnology from Nuvation Bio (NUVB), where he served as CMO.